Newsletter

| September 30, 2009

Bd. of Trs. v. Roche Molecular Sys., Inc.

On September 30, 2009, the Federal Circuit, inter alia, vacated the district court's judgment that U.S. Patents No. 5,968,730, No. 6,503,705, and No. 7,129,041, which related to polymerase chain reaction (PCR) methods of measuring ribonucleic acid (RNA) from human immunodeficiency virus (HIV) in the blood plasma of infected humans who are taking drugs such as zidovudine (AZT), were invalid for obviousness.

This memorandum is intended only as a general discussion of these issues. It is not considered to be legal advice. We would be pleased to provide additional details or advice about specific situations. For additional information on this important topic, please feel free to call upon your Dewey & LeBoeuf relationship partner. No part of this publication may be reproduced, in whole or in part, in any form, without our prior written consent. For further information on Dewey & LeBoeuf, please visit www.dl.com. +1 888 532 6383